Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10557-020-06976-0 http://scihub22266oqcxt.onion/10.1007/s10557-020-06976-0 32318933!7171054!32318933     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cardiovasc+Drugs+Ther 2020 ; 34 (4): 579-584 Nephropedia Template TP {{tp|p=32318933|t=2020. Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare |pdf=|usr=}}{{32318933}} gab.com Text Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare JO: Cardiovasc Drugs Ther http://www.kidney.de/pget.php?&tw=1&pmid=32318933 #FOAvip PURPOSE: Beginning in July of 2018, the FDA issued a voluntary recall regarding the presence of a contaminant found in the manufacturing of valsartan. What would ensue has become a largely unprecedented sequence of alarming events since the FDA began reporting public recalls, withdrawals and safety alerts on their website in 2016. Since then, the United States has been significantly impacted by drug recalls affecting angiotensin receptor blockers. This report arms clinicians with additional guidance and provides a framework for responding appropriately to future similar incidents and includes an overview of the angiotensin receptor blockers, and their effects and safety profiles. METHODS: This report includes a review of data from all pertinent clinical and scientific sources including information from the FDA's inspection documents and recall website. Additional information is provided on the specific bottles including all lot numbers, expiration dates, etc. RESULTS: The recalls/withdrawals are attributable to the presence of cancer-causing contaminants identified during the manufacturing process from drug manufacturers abroad. The root causes behind the recalls and subsequent shortage appear multifactorial, and stem to a certain extent from the outsourcing of medication manufacturing overseas and lack of quality checks and appropriate oversight. CONCLUSIONS: This inherent issue is not likely to resolve soon and has eroded the public trust of/in the healthcare system and the pharmaceutical industry. Patients and healthcare providers are significantly affected and should have a full understanding of the matter in order to guide appropriate response and actions. Twit Text FOAVip Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare ????Cardiovasc Drugs Ther http://www.kidney.de/pget.php?&tw=1&pmid=32318933 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32318933 #FOAvip English Wikipedia <ref>{{Cite pmid|32318933}}</ref> Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare #MMPMID32318933 Gillette M; Taylor A; Butulija D; Kadiyala H; Jneid H Cardiovasc Drugs Ther 2020[Aug]; 34 (4): 579-584 PMID32318933show ga PURPOSE: Beginning in July of 2018, the FDA issued a voluntary recall regarding the presence of a contaminant found in the manufacturing of valsartan. What would ensue has become a largely unprecedented sequence of alarming events since the FDA began reporting public recalls, withdrawals and safety alerts on their website in 2016. Since then, the United States has been significantly impacted by drug recalls affecting angiotensin receptor blockers. This report arms clinicians with additional guidance and provides a framework for responding appropriately to future similar incidents and includes an overview of the angiotensin receptor blockers, and their effects and safety profiles. METHODS: This report includes a review of data from all pertinent clinical and scientific sources including information from the FDA's inspection documents and recall website. Additional information is provided on the specific bottles including all lot numbers, expiration dates, etc. RESULTS: The recalls/withdrawals are attributable to the presence of cancer-causing contaminants identified during the manufacturing process from drug manufacturers abroad. The root causes behind the recalls and subsequent shortage appear multifactorial, and stem to a certain extent from the outsourcing of medication manufacturing overseas and lack of quality checks and appropriate oversight. CONCLUSIONS: This inherent issue is not likely to resolve soon and has eroded the public trust of/in the healthcare system and the pharmaceutical industry. Patients and healthcare providers are significantly affected and should have a full understanding of the matter in order to guide appropriate response and actions. |*Drug Approval[MESH] |*Drug Contamination[MESH] |*Drug Recalls[MESH] |*Quality Control[MESH] |Angiotensin II Type 1 Receptor Blockers/adverse effects/*analysis[MESH] |Carcinogens/*analysis[MESH] |Drug Industry/*standards[MESH] |Humans[MESH] |Patient Safety[MESH] |Risk Assessment[MESH] |Risk Factors[MESH] |United States[MESH]Reflections of the Angiotensin Receptor Blocker Recall by the FDA and (epmc).pdf DeepDyve Pubget Overpricing